Therapeutic potential of curcumin for multiple sclerosis


Multiple sclerosis (MS) is a chronic autoimmune inflammatory disease of the central nervous system (CNS), characterized by demyelination, neuronal injury, and breaching of the blood-brain barrier (BBB). Epidemiological studies have shown that immunological, genetic, and environmental factors contribute to the progression and development of MS. T helper 17 (Th17) cells are crucial immunological participant in the pathophysiology of MS. The aberrant production of IL-17 and IL-22 by Th17 cells crosses BBB promotes its disruption and interferes with transmission of nerve signals through activation of neuroinflammation in the CNS. These inflammatory responses promote demyelination through transcriptional activation of signal transducers and activators of transcription-1 (STAT-1), nuclear factor kappa-B (NF-κB), matrix metalloproteinases (MMPs), interferon ϒ (IFNϒ), and Src homology region 2 domain-containing phosphatase-1 (SHP-1). B cells also contribute to disease progression through abnormal regulation of antibodies, cytokines, and antigen presentation. Additionally, oxidative stress has been known as a causative agent for the MS. Curcumin is a hydrophobic yellowish diphenolic component of turmeric, which can interact and modulate multiple cell signaling pathways and prevent the development of various autoimmune neurological diseases including MS. Studies have reported curcumin as a potent anti-inflammatory, antioxidant agent that could modulate cell cycle regulatory proteins, enzymes, cytokines, and transcription factors in CNS-related disorders including MS. The current study summarizes the reported knowledge on therapeutic potential of curcumin against MS, with future indication as neuroprotective and neuropharmacological drug.

This is a preview of subscription content, log in to check access.

Fig. 1


  1. 1.

    Haider L, Zrzavy T, Hametner S et al (2016) The topograpy of demyelination and neurodegeneration in the multiple sclerosis. Brain 139:807–815.

    Article  PubMed  PubMed Central  Google Scholar 

  2. 2.

    Browne P, Chandraratna D, Angood C et al (2014) Atlas of multiple sclerosis 2013: a growing global problem with widespread inequity. Neurology 83:1022–1024.

    Article  PubMed  PubMed Central  Google Scholar 

  3. 3.

    Jadidi-Niaragh F, Mirshafiey A (2011) Th17 cell, the new player of neuroinflammatory process in multiple sclerosis. Scand J Immunol 74:1–13.

    CAS  Article  PubMed  Google Scholar 

  4. 4.

    Jäger A, Dardalhon V, R a S et al (2009) Th1, Th17, and Th9 effector cells induce experimental autoimmune encephalomyelitis with different pathological phenotypes. J Immunol 183:7169–7177.

    Article  PubMed  PubMed Central  Google Scholar 

  5. 5.

    Elyaman W, Bradshaw EM, Uyttenhove C et al (2009) IL-9 induces differentiation of TH17 cells and enhances function of FoxP3+ natural regulatory T cells. Proc Natl Acad Sci U S A 106:12885–12890.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  6. 6.

    Wekerle H (2017) B cells in multiple sclerosis. Autoimmunity 50:57–60.

    CAS  Article  PubMed  Google Scholar 

  7. 7.

    Von Geldern G, Mowry EM (2012) The influence of nutritional factors on the prognosis of multiple sclerosis. Nat Rev Neurol 8:678–689.

    Article  Google Scholar 

  8. 8.

    Iwu, Maurice M (2014) Handbook of African medcinal plants

    Google Scholar 

  9. 9.

    Costa SL, Silva VDA, dos Santos Souza C et al (2016) Impact of plant-derived flavonoids on neurodegenerative diseases. Neurotox Res 30:41–52.

    CAS  Article  PubMed  Google Scholar 

  10. 10.

    Ginwala R, McTish E, Raman C et al (2016) Apigenin, a natural flavonoid, attenuates EAE severity through the modulation of dendritic cell and other immune cell functions. J NeuroImmune Pharmacol 11:36–47.

    Article  PubMed  Google Scholar 

  11. 11.

    Zhang Y, Li X, Ciric B et al (2015) Therapeutic effect of baicalin on experimental autoimmune encephalomyelitis is mediated by SOCS3 regulatory pathway. Sci Rep 5:17407.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  12. 12.

    Ghaiad HR, Nooh MM, El-Sawalhi MM, Shaheen A a (2016) Resveratrol promotes remyelination in cuprizone model of multiple sclerosis: biochemical and histological study. Mol Neurobiol 1–11.

  13. 13.

    Mrvová N, Škandík M, Kuniaková M, Račková L (2015) Modulation of BV-2 microglia functions by novel quercetin pivaloyl ester. Neurochem Int 90:246–254.

    Article  PubMed  Google Scholar 

  14. 14.

    Barbierato M, Facci L, Marinelli C et al (2015) Co-ultramicronized palmitoylethanolamide/luteolin promotes the maturation of oligodendrocyte precursor cells. Sci Rep 5:16676.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  15. 15.

    Zhang K, Ge Z, Xue Z et al (2015) Chrysin suppresses human CD14+ monocyte-derived dendritic cells and ameliorates experimental autoimmune encephalomyelitis. J Neuroimmunol 288:13–20.

    CAS  Article  PubMed  Google Scholar 

  16. 16.

    Wang WW, Lu L, Bao TH et al (2016) Scutellarin alleviates behavioral deficits in a mouse model of multiple sclerosis, possibly through protecting neural stem cells. J Mol Neurosci 58:210–220.

    CAS  Article  PubMed  Google Scholar 

  17. 17.

    Ciftci O, Ozcan C, Kamisli O, Nese C (2015) Hesperidin, a citrus flavonoid, has the ameliorative effects against experimental autoimmune encephalomyelitis (EAE) in a C57BL / J6 mouse model. Neurochem Res 40:1111–1120.

    CAS  Article  PubMed  Google Scholar 

  18. 18.

    Shen R, Deng W, Li C, Zeng G (2015) A natural flavonoid glucoside icariin inhibits Th1 and Th17 cell differentiation and ameliorates experimental autoimmune encephalomyelitis. Int Immunopharmacol 24:224–231.

    CAS  Article  PubMed  Google Scholar 

  19. 19.

    Seyedzadeh MH, Safari Z, Zare A et al (2014) Study of curcumin immunomodulatory effects on reactive astrocyte cell function. Int Immunopharmacol 22:230–235.

    CAS  Article  PubMed  Google Scholar 

  20. 20.

    Cheng KK, Yeung CF, Ho SW et al (2013) Highly stabilized curcumin nanoparticles tested in an in vitro blood-brain barrier model and in Alzheimer’s disease Tg2576 mice. AAPS J 15:324–336.

    CAS  Article  PubMed  Google Scholar 

  21. 21.

    Monroy A, Lithgow GJ, Alavez S (2013) Curcumin and neurodegenerative diseases. Biofactors 39:122–132.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  22. 22.

    Calabrese M, Magliozzi R, Ciccarelli O et al (2015) Exploring the origins of grey matter damage in multiple sclerosis. Nat Rev Neurosci 16:147–158.

    CAS  Article  PubMed  Google Scholar 

  23. 23.

    Tavazzi E, Laganà MM, Bergsland N et al (2014) Grey matter damage in progressive multiple sclerosis versus amyotrophic lateral sclerosis: a voxel-based morphometry MRI study. Neurol Sci 36:371–377.

    Article  PubMed  Google Scholar 

  24. 24.

    Incerti CC, Argento O, Magistrale G et al (2016) Adverse working events in patients with multiple sclerosis. Neurol Sci 38:1–4.

    Google Scholar 

  25. 25.

    Kutzelnigg A, Lassmann H (2014) Pathology of multiple sclerosis and related inflammatory demyelinating diseases, 1st ed. Handb Clin Neurol.

  26. 26.

    KG S, Banker G, Bourdette D, Forte M (2009) Axonal degeneration in multiple sclerosis: the mitochondrial hypothesis. Curr Neurol Neurosci Rep 9:411–417.

    Article  Google Scholar 

  27. 27.

    Ingram G, Loveless S, Howell OW et al (2014) Complement activation in multiple sclerosis plaques: an immunohistochemical analysis. Acta Neuropathol Commun 2:53.

    Article  PubMed  PubMed Central  Google Scholar 

  28. 28.

    Mirshafiey A, Asghari B, Ghalamfarsa G et al (2014) The significance of matrix metalloproteinases in the immunopathogenesis and treatment of multiple sclerosis. Sultan Qaboos Univ Med J 14:13–25

    Article  Google Scholar 

  29. 29.

    Gilgun-Sherki Y, Melamed E, Offen D (2004) The role of oxidative stress in the pathogenesis of multiple sclerosis: the need for effective antioxidant therapy. J Neurol 251:261–268.

    CAS  Article  PubMed  Google Scholar 

  30. 30.

    Christophi GP, Panos M, C a H et al (2009) Macrophages of multiple sclerosis patients display deficient SHP-1 expression and enhanced inflammatory phenotype. Lab Investig 89:742–759.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  31. 31.

    Kolls JK, Linde A (2004) Interleukin-17 family members. Immunity 21:467–476.

    CAS  Article  PubMed  Google Scholar 

  32. 32.

    Miljkovic D, Cvetkovic I, Momcilovic M et al (2005) Interleukin-17 stimulates inducible nitric oxide synthase-dependent toxicity in mouse beta cells. Cell Mol Life Sci 62:2658–2668.

    CAS  Article  PubMed  Google Scholar 

  33. 33.

    Li J, Gran B, Zhang GX et al (2003) Differential expression and regulation of IL-23 and IL-12 subunits and receptors in adult mouse microglia. J Neurol Sci 215:95–103.

    CAS  Article  PubMed  Google Scholar 

  34. 34.

    Anagnostouli M, Christidi F, Zalonis I et al (2015) Clinical and cognitive implications of cerebrospinal fluid oligoclonal bands in multiple sclerosis patients. Neurol Sci 36:2053–2060.

    Article  PubMed  Google Scholar 

  35. 35.

    Hao J, Liu R, Piao W et al (2010) Central nervous system (CNS)-resident natural killer cells suppress Th17 responses and CNS autoimmune pathology. J Exp Med 207:1907–1921.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  36. 36.

    Liu Q, Sanai N, Jin W-N, et al (2016) Neural stem cells sustain natural killer cells that dictate recovery from brain inflammation. Nat Neurosci 1–12.

  37. 37.

    Ortiz GG, Pacheco-mois P, Angel M et al (2014) Role of the blood e brain barrier in multiple sclerosis. Arch Med Res.

  38. 38.

    Kebir H, Kreymborg K, Ifergan I et al (2007) Human TH17 lymphocytes promote blood-brain barrier disruption and central nervous system inflammation. Nat Med 13:1173–1175.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  39. 39.

    Huppert J, Closhen D, Croxford A et al Cellular mechanisms of IL-17-induced blood-brain barrier disruption. FASEB J.

  40. 40.

    Priyadarsini KI (2014) The chemistry of curcumin: from extraction to therapeutic agent. Molecules 19:20091–20112.

    Article  PubMed  Google Scholar 

  41. 41.

    Federico A, Cardaioli E, Da Pozzo P et al (2012) Mitochondria, oxidative stress and neurodegeneration. J Neurol Sci 322:254–262.

    CAS  Article  PubMed  Google Scholar 

  42. 42.

    Follett J, Bugarcic A, Yang Z et al (2016) Parkinson’s disease linked Vps35 R524W mutation impairs the endosomal association of retromer and induces α -synuclein aggregation. J Biol Chem 291:18283–18298.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  43. 43.

    Palmqvist S, Mattsson N, Hansson O (2016) Cerebrospinal fluid analysis detects cerebral amyloid-ß accumulation earlier than positron emission tomography. Brain 139:1226–1236.

    Article  PubMed  PubMed Central  Google Scholar 

  44. 44.

    Bates G (2003) Huntingtin aggregation and toxicity in Huntington’s disease. Lancet 361:1642–1644.

    CAS  Article  PubMed  Google Scholar 

  45. 45.

    Farina M, Avila DS, Da Rocha JBT, Aschner M (2013) Metals, oxidative stress and neurodegeneration: a focus on iron, manganese and mercury. Neurochem Int 62:575–594.

    CAS  Article  PubMed  Google Scholar 

  46. 46.

    Chin-Chan M, Navarro-Yepes J, Quintanilla-Vega B (2015) Environmental pollutants as risk factors for neurodegenerative disorders: Alzheimer and Parkinson diseases. Front Cell Neurosci 9:124.

    Article  PubMed  PubMed Central  Google Scholar 

  47. 47.

    Fischer R, Maier O (2015) Interrelation of oxidative stress and inflammation in neurodegenerative disease: role of TNF. Oxidative Med Cell Longev 2015:1–18

    CAS  Article  Google Scholar 

  48. 48.

    Zhou H, Beevers CS, Huang S (2011) The targets of curcumin. Curr Drug Targets 12:332–347

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  49. 49.

    Chen J-J, Dai L, Zhao L-X et al (2015) Intrathecal curcumin attenuates pain hypersensitivity and decreases spinal neuroinflammation in rat model of monoarthritis. Sci Rep 5:10278.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  50. 50.

    Ma QL, Zuo X, Yang F et al (2013) Curcumin suppresses soluble Tau dinners and corrects molecular chaperone, synaptic, and behavioral deficits in aged human Tau transgenic mice. J Biol Chem 288:4056–4065.

    CAS  Article  PubMed  Google Scholar 

  51. 51.

    Farooqui, A A (2016) Therapeutic potentials of curcumin for Alzheimer disease.–3–319-15889-1

  52. 52.

    Ji H-F, Shen L (2014) The multiple pharmaceutical potential of curcumin in Parkinson’s disease. CNS Neurol Disord Drug Targets 13:369–373.

    CAS  Article  PubMed  Google Scholar 

  53. 53.

    Chongtham A, Agrawal N (2016) Curcumin modulates cell death and is protective in Huntington’s disease model. Sci Rep 6:18736.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  54. 54.

    Wu A, Noble EE, Tyagi E et al (2015) Curcumin boosts DHA in the brain: implications for the prevention of anxiety disorders. BBA Mol Basis Dis 1852:951–961.

    CAS  Article  Google Scholar 

  55. 55.

    Xie L, Li XK, Funeshima-Fuji N et al (2009) Amelioration of experimental autoimmune encephalomyelitis by curcumin treatment through inhibition of IL-17 production. Int Immunopharmacol 9:575–581.

    CAS  Article  PubMed  Google Scholar 

  56. 56.

    Yu HJ, Lan Ma JJ, SQS (2016) Protective effect of curcumin on neural myelin sheaths by attenuating interactions between the endoplasmic reticulum and mitochondria after compressed spinal cord. J Spine 5:2.

    Google Scholar 

  57. 57.

    Kim G-Y, Kim K-H, Lee S-H et al (2005) Curcumin inhibits Immunostimulatory function of dendritic cells: MAPKs and translocation of NF- B as potential targets. J Immunol 174:8116–8124.

    CAS  Article  PubMed  Google Scholar 

  58. 58.

    Orrenius S, Gogvadze V, Zhivotovsky B (2007) Mitochondrial oxidative stress: implications for cell death. Annu Rev Pharmacol Toxicol 47:143–183.

    CAS  Article  PubMed  Google Scholar 

  59. 59.

    Chearwae W, Bright JJ (2008) 15-Deoxy- Δ 12, 14 -prostaglandin J 2 and curcumin modulate the expression of toll-like receptors 4 and 9 in autoimmune T lymphocyte. J Clin Immunol 28:558–570.

    CAS  Article  PubMed  Google Scholar 

  60. 60.

    Natarajan C, Bright JJ (2002) Curcumin inhibits experimental allergic encephalomyelitis by blocking IL-12 signaling through Janus kinase-STAT pathway in T lymphocytes. J Immunol 168:6506–6513.

    CAS  Article  PubMed  Google Scholar 

  61. 61.

    Kanakasabai S, Casalini E, Walline CC et al (2012) Differential regulation of CD4 + T helper cell responses by curcumin in experimental autoimmune encephalomyelitis. J Nutr Biochem 23:1498–1507.

    CAS  Article  PubMed  Google Scholar 

  62. 62.

    Feng J, Tao T, Yan W et al (2014) Curcumin inhibits mitochondrial injury and apoptosis from the early stage in EAE mice. Oxidative Med Cell Longev 2014:1–11.

    Article  Google Scholar 

  63. 63.

    Abbott NJ (2002) Astrocyte-endothelial interactions and blood-brain barrier permeability. J Anat 200:629–638.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  64. 64.

    Jin CY, Lee JD, Park C et al (2007) Curcumin attenuates the release of pro-inflammatory cytokines in lipopolysaccharide-stimulated BV2 microglia. Acta Pharmacol Sin 28:1645–1651.

    CAS  Article  PubMed  Google Scholar 

  65. 65.

    Agrawal SM, Lau L, Yong VW (2008) MMPs in the central nervous system: where the good guys go bad. Sem Cell Dev Biol 19:42–51.

    CAS  Article  Google Scholar 

  66. 66.

    Zhang ZJ, Zhao LX, Cao DL et al (2012) Curcumin inhibits LPS-induced CCL2 expression via JNK pathway in C6 rat astrocytoma cells. Cell Mol Neurobiol 32:1003–1010.

    CAS  Article  PubMed  Google Scholar 

  67. 67.

    Kimura K, Teranishi S, Fukuda K et al (2008) Delayed disruption of barrier function in cultured human corneal epithelial cells induced by tumor necrosis factor-alpha in a manner dependent on NF-kappaB. Invest Ophthalmol Vis Sci 49:565–571.

    Article  PubMed  Google Scholar 

  68. 68.

    Carlson T, Kroenke M, Rao P et al (2008) The Th17-ELR+ CXC chemokine pathway is essential for the development of central nervous system autoimmune disease. J Exp Med 205:811–823.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  69. 69.

    Bachmeier BE, Mohrenz IV, Mirisola V et al (2008) Curcumin downregulates the inflammatory cytokines CXCL1 and -2 in breast cancer cells via NFκB. Carcinogenesis 29:779–789.

    CAS  Article  PubMed  Google Scholar 

  70. 70.

    Kamohara H, Takahashi M, Ishiko T et al (2007) Induction of interleukin-8 (CXCL-8) by tumor necrosis factor-alpha and leukemia inhibitory factor in pancreatic carcinoma cells: impact of CXCL-8 as an autocrine growth factor. Int J Oncol 31:627–632

    CAS  PubMed  Google Scholar 

  71. 71.

    Choi KH, Park JW, Kim HY et al (2010) Cellular factors involved in CXCL8 expression induced by glycated serum albumin in vascular smooth muscle cells. Atherosclerosis 209:58–65.

    CAS  Article  PubMed  Google Scholar 

  72. 72.

    Liu H, Yang J, Li L et al (2016) The natural occurring compounds targeting endoplasmic reticulum stress. J Evid Based Complementary Altern Med 1113:58–71.

    Google Scholar 

  73. 73.

    Zheng M, Zhang Q, Joe Y et al (2013) Curcumin induces apoptotic cell death of activated human CD4 + T cells via increasing endoplasmic reticulum stress and mitochondrial dysfunction. Int Immunopharmacol 15:517–523.

    CAS  Article  PubMed  Google Scholar 

  74. 74.

    Tegenge MA, Rajbhandari L, Shrestha S et al (2014) Curcumin protects axons from degeneration in the setting of local neuroinflammation. Exp Neurol 253:102–110.

    CAS  Article  PubMed  Google Scholar 

  75. 75.

    Baker M (2016) Chemists warn against deceptive molecules: spice extract curcumin dupes assays and leads some drug hunters astray. Nature 541:144–145

    Article  Google Scholar 

  76. 76.

    Nelson KM, Dahlin JL, Bisson J et al (2017) The essential medicinal chemistry of curcumin. J Med Chem 60:1620.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  77. 77.

    Series AC (2008) Letters to the editors suicidal ideation associated with duloxetine use successful treatment of nicotine withdrawal with duloxetine a case report. J Clin Pharmacol 28:101–122

    Google Scholar 

  78. 78.

    Ringman JM, S a F, Teng E et al (2012) Oral curcumin for Alzheimer’s disease: tolerability and efficacy in a 24-week randomized, double-blind, placebo-controlled study. Alzheimers Res Ther 4:43.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information



Corresponding author

Correspondence to Adeeb Shehzad.

Ethics declarations

Competing interests

The authors declare that they have no conflict of interest.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Qureshi, M., Al-Suhaimi, E.A., Wahid, F. et al. Therapeutic potential of curcumin for multiple sclerosis. Neurol Sci 39, 207–214 (2018).

Download citation


  • Curcumin
  • Multiple sclerosis
  • Autoimmunediseases
  • Th-17cells
  • B cells
  • Oxidative stress